CompanyAmphivena Therapeutics, Inc. is an immuno-oncology company based in South San Francisco, CA that is developing best-in-class T-cell engagers. The company’s lead drug candidate, AMV564, is a bivalent, bispecific CD33/ CD3 T cell engager that is selective for leukemic blasts and myeloid derived suppressor cells (MDSC), sparing normal myeloid cells (e.g., neutrophils and monocytes). To date, over 60 patients have received AMV564 across three Phase 1 clinical trials for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and solid tumors. Amphivena’s mission is to eradicate cancers with breakthrough therapies that harness the patient’s own immune system to destroy tumor cells and their precursors.
We are seeking a motivated researcher to work in the development of novel therapeutics harnessing the immune system to eliminate cancer. You will participate in and help develop the scientific direction of research to identify and evaluate novel therapeutics. You will advance the pipeline through protein engineering and analyses of the physical properties of our bivalent, bispecific T cell engagers, to generate and identify superior clinical candidates for development.
Please send your CV to email@example.com